Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02036645 · ClinicalTrials.gov registry record · Phase 1
SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.
A Phase 1 study of Healthy Elderly and Mild-Moderate Alzheimer's Disease, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
- 10
- Study locations
NCT02036645: Completed Phase 1 study of Healthy Elderly and Mild-Moderate Alzheimer's Disease, sponsored by AstraZeneca.
NCT02036645 is a Phase 1 study of Healthy Elderly and Mild-Moderate Alzheimer's Disease that has completed, run by AstraZeneca. The registered enrollment target is 77 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% higher). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02036645, a Phase 1 study of Healthy Elderly and Mild-Moderate Alzheimer's Disease, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to assess the safety, drug levels and effects on the body of 1 or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy elderly people.
Primary Outcome
Tolerability measured by participant withdrawal for an adverse event from randomization through end of study
Conditions Studied
Interventions
- BIOLOGICAL MEDI1814 for IV injection
- BIOLOGICAL MEDI1814 for Subcutaneous Injection
- BIOLOGICAL IV Placebo
- BIOLOGICAL Placebo for Subcutaneous Injection
Study Locations (10)
Florida
- Research Site - Hallandale
- Research Site - Hialeah
- Research Site - Miami
- Research Site - Orlando
California
- Research Site - Glendale
- Research Site - Long Beach
- Research Site - Panorama City
Maryland
- Research Site - Baltimore
Oklahoma
- Research Site - Oklahoma City
Utah
- Research Site - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2014-02-04 |
| Est. Completion | 2016-09-15 |
| Phase | Phase 1 |
What the finished NCT02036645 record still lists
NCT02036645 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% higher).
The record links to 2 conditions, with Healthy Elderly appearing as the primary indexed condition, and to 4 interventions - of which MEDI1814 for IV injection is the first listed.
NCT02036645 lists 10 locations in 5 states (Florida, California, Maryland).
Frequently Asked Questions
What is clinical trial NCT02036645 about?
NCT02036645 is a clinical study titled "SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.". The purpose of this study is to assess the safety, drug levels and effects on the body of 1 or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy elderly people.
What is the current status of trial NCT02036645?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2014-02-04. Estimated completion is 2016-09-15.
What conditions does trial NCT02036645 study?
This clinical trial studies the following conditions: Healthy Elderly, Mild-Moderate Alzheimer's Disease.
What interventions are being tested in trial NCT02036645?
The interventions under investigation include: MEDI1814 for IV injection (BIOLOGICAL), MEDI1814 for Subcutaneous Injection (BIOLOGICAL), IV Placebo (BIOLOGICAL), Placebo for Subcutaneous Injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT02036645?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02036645 being conducted?
This trial has 10 study locations across California, Florida, Maryland, Oklahoma, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Elderly
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02036645's enrollment target sits among peer trials
77 703rd of 2000 higher than 1,296 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI